Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The tendon-to-bone healing interface is notoriously weak, and retear rates remain high even after technically successful surgery
BPC-157 stands out for its direct bone healing evidence in animal models, its dual angiogenic and osteogenic effects, and its favorable safety profile across a wide dosing range
There was a negative correlation between IL-6 levels and brachial artery flow-mediated dilation, an effect that was improved by treatment with tocilizumab, an IL-6 inhibitor
Our customer service team will reach out for more information as needed
US$ 25.63
US$ 22.98
US$ 26.02
US$ 29.09
